Sanofi–GSK COVID-19 vaccine

The Sanofi–GSK COVID-19 vaccine code-named VAT00002 and VAT00008 (with adjuvant)[1] is a COVID-19 vaccine candidate developed by Sanofi Pasteur and GSK.[2]

Sanofi–GSK COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Trade namesVidprevtyn
Other namesVAT00002, VAT00008
Routes of
administration		Intramuscular
ATC code
Identifiers
DrugBank
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
  • January
    • responses
  • February
    • responses
  • March
    • responses
  • April
    • responses
  • May
    • responses
  • June
    • responses
  • July
    • responses
  • August
    • responses
  • September
    • responses
  • October
    • responses
  • November
    • responses
  • December
    • responses
2021
2022
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
  • Association football
  • Baseball
  • Basketball
  • Combat sports
  • Cricket
  • Disc golf
  • Gaelic games
  • Gridiron football
  • Ice hockey
  • Motorsport
  • Rugby league
Impacts
Society
 COVID-19 portal

Pharmacology

VAT00008 is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine.[3][4]

History

VAT00008 is under development by the French pharmaceutical company Sanofi and the British-American pharmaceutical company GlaxoSmithKline.[5] Advanced clinical trials of the vaccine were delayed in December 2020 after it failed to produce a strong immune response in people over the age of 50, most likely due to an insufficient antigen concentration in the vaccine, delaying the launch of the vaccine to late 2021.[6]

Clinical trials

In September 2020, Sanofi-GSK started for phase I trials with 440 participants in the United States.[7]

In February 2021, Sanofi-GSK started for phase II trials with 722 participants in the United States.[8]

On 27 May 2021, the vaccine began a Phase III trial involving 35,000 participants,[9][10][11] which increased to 37,430 participants with trials in Colombia, Dominican Republic, Ghana, Honduras, India, Japan, Kenya, Mexico,[12] Nigeria, Pakistan, Sri Lanka, Uganda, and the United States.[13]

In September 2021, Sanofi-GSK started a booster trial in the United Kingdom. In this study, they will enroll up to 3,145 volunteers who have previously completed a COVID-19 a full vaccine course between 4 and 10 months previously. The purpose of this study is to determine if the investigational COVID-19 vaccines are safe and can stimulate and broaden the immune response against the different COVID-19 variants that cause COVID-19 when given as a single booster injection in participants who have previously been vaccinated with a full course of an authorized COVID-19 vaccine.[14]

Society and culture

In July 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started a rolling review of Vidprevtyn, a COVID-19 vaccine developed by Sanofi Pasteur.[15] The CHMP's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults, which suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease.[15]

Economics

In July 2020, the UK government signed up for 60 million doses of a COVID-19 vaccine developed by GSK and Sanofi. It uses a recombinant protein-based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021.[16] The company also agreed to a $2.1 billion deal with the United States to produce 100 million doses of the vaccine.[17]

References
  1. "Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)". ClinicalTrials.gov. Retrieved 28 May 2021.
  2. "Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older". pactr.samrc.ac.za. Pan African Clinical Trials Registry. Retrieved 24 March 2021.{{cite web}}: CS1 maint: url-status (link)
  3. "Sanofi, GSK announce positive results for Covid-19 vaccine candidate". STAT. 17 May 2021. Retrieved 18 May 2021.
  4. "The Adjuvanted Recombinant Protein-based Vaccine Candidate". Sanofi. Retrieved 18 May 2021.
  5. "Coronavirus vaccine trial begun by drug firms GSK and Sanofi". BBC News Online. 3 September 2020. Retrieved 20 April 2021.
  6. Taylor NP (11 December 2020). "Weak clinical data force Sanofi, GSK to delay COVID-19 vaccine". Fierce Biotech. Retrieved 25 January 2021.
  7. "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older". ClinicalTrials.gov. 3 September 2020. NCT04537208.
  8. "Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)". ClinicalTrials.gov. 21 February 2021. NCT04762680.
  9. Armitage, Jim (27 May 2021). "GlaxoSmithKline shareholders "relieved" as Elliott rules out aggressive demands". London Evening Standard.
  10. "Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate". Sanofi (Press release). 27 May 2021. Retrieved 22 July 2021.
  11. "Phase 3 Clinical Trial for COVID-19 Recombinant Protein Vaccine Candidate". Sanofi. Retrieved 22 July 2021.
  12. "Tarjeta del participante del estudio VAT00008: ejemplo central para adaptación a nivel de país" [VAT00008 Study Participant Card: Central Example for Country-Level Adaptation] (PDF). incmnsz.mx. Salvador Zubirán National Institute of Health Sciences and Nutrition. 15 April 2021.
  13. "Safety and efficacy of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older". ctri.nic.in. Clinical Trials Registry India. CTRI/2021/06/034442. Retrieved 3 August 2021.
  14. "Covid-19 Booster Vaccine Clinical Study". Sanofi. 22 October 2021. Archived from the original on 30 October 2021. Retrieved 22 October 2021.
  15. "EMA starts rolling review of COVID-19 vaccine Vidprevtyn". European Medicines Agency (EMA) (Press release). 20 July 2021. Retrieved 22 July 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  16. "Coronavirus vaccine: UK signs deal with GSK and Sanofi". BBC News. 29 July 2020.
  17. Lovelace Jr B (31 July 2020). "U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine". CNBC.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.